European panel backs Janssen’s psoriasis drug

(Reuters) – A European Medicines Agency (EMA) panel recommended the approval of Johnson & Johnson unit Janssen's drug, guselkumab, for the treatment of plaque psoriasis in adults.
Original Article

more recommended stories